Redeye comments on Sivers’ announcement about its Photonics business will be separated and merged in...
Redeye states the report was solid, beating its net sales forecast by 25% and growing 19% y/y despit...
Redeye updates its estimates and valuation following Freemelt’s Q2 report, which came in below our e...
Redeye states that CoinShares' (CS) report was solid with beats across the board except for the end ...
NoHo Partners' Q2 2024 results missed the Vara Research consensus' high expectations, but we neverth...
Q2 EBITDA 8% above on lower costs Reduced guidance, yet only small changes to estimates Reiterate fa...
Redeye is positive to the news of FiiZK divesting its lice skirt business FiiZK Protection AS.
Q2e: Wood acquisition drives sales and earnings growth We cut adj.
Q2 adj. EBIT of GBP 26m, below ABGSCe at GBP 35m Slight AUM miss driven by CS Physical Q2 worse than...
Q2 production slightly below Focus in Q2: Exploration, FDP on Block 56 & strategic review P/NAV of 0...
Redeye comments on Freemelt’s Q2 results, which came in lower than expected because some anticipated...
Sales SEK 2.4m vs. cons. 13m due to incomplete eMELT-iD delivery EBIT adj.
Net sales and EBIT were slightly below consensus (LSEG) in Q2.
NoHo Partners reported Q2 EBIT of EUR 9.7m (-9% y/y), 17% below Vara Research consensus and 20% belo...
We expect positive group revenue growth in Q2 after a decline for the last four quarters on a y/y ba...
Svagare utveckling än väntat Adtraction minskade omsättningen med 14,5 procent i det andra kvartalet...
Mangold uppdaterar sin syn på sensorteknikbolaget JonDeTech Sensors (JonDeTech) efter det andra kvar...
We maintain our estimates intact ahead of Suominen’s Q2 report, due on 9 August.
Redeye notes a weak Q2 for Sedana Medical, with lower sales and higher costs than we expected.
Føroya Banki delivered a solid Q2 2024 result with net profit of DKK 87m, DKK 19m above our estimate...